Tetsuro Kikuchi

Research Field

Malignant astrocytoma is the most common primary brain tumor in adults. The median survival time of patients with high-grade malignant astrocytoma is about 1 year, despite aggressive treatment with surgical resection, radiotherapy, and cytotoxic chemotherapy. Novel therapeutic approaches are therefore needed to prolong survival. Immunotherapy is one such novel approach that has been investigated for application with different types of tumors, including brain tumors. The author reviews immunotherapeutic approaches for malignant gliomas and the relevance of recent clinical trials and their outcomes. A number of potentially targetable antigens have been identified in gliomas. Both tenascin and epidermal growth factor receptor (EGFR) have been studied extensively as targets for direct immune attack via specific antibodies. As a novel target, interleukin 13 receptor alpha 2-chain (IL-13 R alpha 2) has been identified. IL-13 R alpha 2 is abundantly and specifically overexpressed in glioblastoma multiforme, and recently a MHC class I-restricted CTL epitope has been identified. Dendritic cells (DCs) are professional antigen presenting cells (APCs) that have a unique potency for activating T cells. DCs have been investigated in several clinical trials in patients with malignant tumors including malignant gliomas. So far, seven papers concerning immunotherapy with DCs against malignant gliomas have been published. These reports demonstrate that immunotherapy with DCs induces immune responses and clinically antitumor effects in some patients with malignant glioma. In addition, none of these studies reported evidence of autoimmune neurotoxicity.

Brain tumor

Temozolomide

Source

Cite

Citations (2)

Aripiprazole: A dopamine-serotonin system stabilizer

Schizophrenia Research (2003)

Nobuyuki Kurahashi Robert D. McQuade Kevin D. Burris Sue Jordan Katsura Tottori

Translocator protein

10.1016/s0920-9964(03)80255-4

Cite

Citations (15)

Le prix Galien 2006 décerné à Abilify®

L information psychiatrique (2006)

Tetsuro Kikuchi Anne‐Laure Simonnot

10.1684/ipe.2006.0066

Cite

Citations (0)

Protective effects of OPC-14117 on dopaminergic neuronal degeneration induced by MPTP in ICR mice

The Japanese Journal of Pharmacology (1995)

Kaisura Tottori Tetsuro Kikuchi Yasufumi Uwahodo Masami Nakai Takashi Miwa

MPTP

Degeneration (medical)

Neuronal Degeneration

10.1016/s0021-5198(19)46540-2

Cite

Citations (4)

Differences in the effects of chronic treatments with aripiprazole on dopamine D2 receptors between in the rat striatum and pituitary.

The Japanese Journal of Pharmacology (1996)

Mayumi Seto Atsuko Inoue Tetsuro Kikuchi Seiji Morita Yoshihiro Nakata

Aripiprazole

10.1016/s0021-5198(19)37003-9

Cite

Citations (0)

ChemInform Abstract: Novel Cerebroprotective Agents with Central Nervous System Stimulating Activity. Part 1. Synthesis and Pharmacology of 1‐Amino‐7‐hydroxyindan Derivatives.

ChemInform (1991)

Y. Oshiro Y. SAKURAI T. TANAKA Hajime Ueda Tetsuro Kikuchi

Abstract ChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 100 leading journals. To access a ChemInform Abstract of an article which was published elsewhere, please select a “Full Text” option. The original article is trackable via the “References” option.

10.1002/chin.199152160

Cite

Citations (0)

In vitro profile of the antidepressant candidate OPC-14523 at rat and human 5-HT1A receptors

European Journal of Pharmacology (2005)

Shaun Jordan Ruoyan Chen Vuk Koprivica Ronald L. Hamilton Richard Whitehead

5-HT1A receptor

8-OH-DPAT

Mechanism of Action

10.1016/j.ejphar.2005.05.035

Cite

Citations (7)